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We were interested by the article from De Corte et
al. about the poor long-term outcome after acute kid-
ney injury (AKI) [1]. Besides initial oliguria, the three
predictors for dialysis dependence were age, diabetes,
and chronic kidney disease (CKD), which have previ-
ously been related to the accumulation of advanced
glycation end-products (AGEs) as evaluated by skin
autofluorescence (sAF). sAF is an indirect marker that
has been related to the skin concentrations of fluores-
cent (pentosidine) and non-fluorescent AGEs (car-
boxy-methyl-lysine and carboxy-ethyl-lysine) in skin
biopsies of hemodialized subjects [2]. Could sAF be
altered in AKI?
From July 2014 to April 2015, we measured sAF
with an AGE-Reader (DiagnOpticsTechnologies B.V.,
Groningen, Netherlands) in 35 patients admitted for
AKI, staged F (RIFLE). Their results were compared to
their theoretical values ((0.024 × Years of age) + 0.83
[3]) and to those of 35 patients with CKD waiting for
a renal graft. All the patients gave written informed
consent and the study was approved by the Comité de
Protection des Personnes Sud-Ouest et Outre-Mer 3
(Bordeaux). A multivariate linear regression analysis
was performed to study the relationship between sAF
and the duration of renal failure and to adjust it to the
age and gender of the subjects.
The patients with AKI and CKD had similar age,
gender, body-mass index, and creatinine levels
(Table 1). The sAF was lower in AKI than CKD, still
significant (p < 0.001) after adjustment for age, gender,
and creatinine. The sAF were higher than the theoret-
ical values calculated from age: 2.31 ± 0.36 arbitrary
units (AU; p < 0.001 for both AKI and CKD). The
sAF was related to the duration of renal failure and
was still significant (B = +0.43, p = 0.02) after adjust-
ment for age and gender (Fig. 1). In six patients with
AKI, a second sAF measurement was performed10 ±
3 days later: the sAF increased from 2.61 ± 0.72 to
3.03 ± 0.74 (p < 0.05).
Our results show that sAF is lower in AKI than in
CKD and relates to the duration of renal failure, as
expected. sAF is considered as a marker of metabolic
memory [4], reflecting the accumulation of AGEs in
the skin [2]. In our patients who could be analyzed
twice, sAF increased by +0.4 AU after only 10 days,
so they probably had normal sAF when their AKI
started one month before. A normal, early measured
sAF may therefore help to distinguish acute from
chronic renal failure. The sAF was already high, and
increased rapidly, in our patients with AKI. This
concurs well with the quick rising plasmatic concen-
trations of AGEs in experimentally induced acute
renal failure in rats [5]. High sAF has also been re-
ported in patients admitted to intensive care units
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Age (years) 62 ± 15 62 ± 10 NS
Gender (percentage of women) 57% 54% NS
Diabetes 31% 34% NS
BMI (kg/m2) 26.5 ± 7.7 24.7 ± 3.8 NS
Serum creatinine (mg/dL) 7.0 ± 3.6 7.1 ± 1.7 NS
Duration of renal failure (days) 34 ± 28 3275 ± 2114 <0.001
Smokers 25% 28% NS
sAF (AU) 2.97 ± 0.72 3.70 ± 0.72 <0.001
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[6], attributed to acute oxidative stress, which occurs
in AKI. Although sAF is an indirect marker and
fluorescent compounds other than AGEs accumulate
in uremia, our results raise the hypothesis that the
accumulation of AGEs during AKI may play a role in
a later adverse outcome.
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